Drug intelligence / Profile preview

chemoradiotherapy + panitumumab

Development stage: Unknown
Lead developer: Amgen
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of chemoradiotherapy (CRT) and panitumumab. Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). This combination has been studied in various cancer types, particularly head and neck cancer and anal squamous cell carcinoma.

Other names: CRT + panitumumab

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on chemoradiotherapy + panitumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chemoradiotherapy + panitumumab.

Explore the full profile